NASH Will Outnumber Transplants for HCV in the Near Future
SILVER SPRING, MD, November 2012 – Between 1997 and 2011, 144 patients underwent liver transplants for NASH (nonalcoholic steatohepatitis called fatty liver) at UCLA representing 12% of all liver transplants with 19% of them being done in 2011.
It is anticipated with the sky-high obesity rate and associated co-morbidities, liver transplants for NASH will soon become the leading indication for liver transplants in the United States, according to Dr. Vathe Agopian at UCLA.
Patients with NASH had more pretransplant co-morbidities than other candidates for liver transplants. These included hypertension, metabolic syndrome, obesity and diabetes. Patients with NASH also required more resources during surgery with longer operative times, greater blood loss and longer postoperative stay in the hospital. However, their outcomes exceeded transplant recipients for hepatitis C. It is strongly recommended that individuals bring their obesity under control.
For more information, contact:
Thelma K. Thiel